Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

d statements of operations: (1) To exclude amortization of commercial intangible assets related to marketed products. (2) To exclude separation costs of $10,459, impairment of long-lived assets of $1,482 and contract termination costs of $540. (3) To exclude upfront and milestone payments to partners of $8,910, separation costs of $825, impairment of long lived assets of $3,115 and contract termination costs of $4,551. (4) To exclude impairment of other intangibles. (5) To exclude purchased in-process research and development. (6) To exclude additional interest expense as a result of adopting ASC 470-20. (7) To exclude changes in fair value of financial instruments, net. (8) To reflect the tax effect of the pre-tax adjustments above at the applicable tax rates. For an explanation of Endo's reasons for using non-GAAP measures, see Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission. Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance Year Ending Dec. 31, 2010 Projected GAAP diluted income per common share $2.40 To $2.45 Upfront and milestone payments to partners $0.12 $0.12 Amortization of commercial intangible assets $0.59 $0.59 Interest expense adjustment for ASC 470-20 and the amortization of the premium on debt acquired from Indevus $0.15 $0.15 Tax effect of pre-tax adjustments at the applicable tax rates and certain other expected cash tax savings as a result of the Indevus acquisition ($0.11) ($0.11) Diluted adjusted income pe
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... on Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") ... of Directors ("Depomed Board") set a record date to ... The Depomed Board will review the ... is received today and contains the information required under ...
(Date:8/3/2015)... YORK , August 3, 2015 ... published by Persistence Market Research "Global Market Study ... to Witness Highest Growth by 2022", the ... US$15 Bn by the end of 2015 and is ... from 2015 to 2022, to account for US$23.7 ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... development portfolio building on lead product ... Phase 2 trial for onychomycosis, WELLESLEY HILLS, Mass., ... announced that it has,exercised the option it acquired in ... uses of pexiganan, a novel, small peptide,anti-infective for treatment ...
... BOULDER, Colo., Oct. 3 Tapestry,Pharmaceuticals, Inc. (Nasdaq: ... 2 open- label, multi-center study of TPI 287 in ... 2 trial exploring the,activity of TPI 287 in various ... year in advanced hormone refractory prostate cancer. "Currently ...
Cached Medicine Technology:MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 2MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 3MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 4MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 5MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 6Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 2Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 3Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 4Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 5
(Date:8/4/2015)... ... August 04, 2015 , ... ... in which the physician is board-certified is increasingly influential in their choice of ... , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer ...
(Date:8/4/2015)... ... 04, 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving ... Be Well videos to preparing high school athletes for fall sports. , In a concise ... as:, , What steps to take to help prevent injuries , ...
(Date:8/4/2015)... , ... August 04, 2015 , ... More than 700 ... renewed their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard ... each other. Following the ceremony was a reception, with music by the Moonlight ...
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking younger – ... for invasive surgery to achieve this ideal is not. But minimally invasive procedures such ... the high cost or lengthy recovery time, according to Valerie Goldburt, MD, PhD ...
(Date:8/4/2015)... ... August 04, 2015 , ... In ... filed against Johnson & Johnson report that a new location for pretrial proceedings ... regular news updates and cancer warning information at their website, the Talcum Powder ...
Breaking Medicine News(10 mins):Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4
... Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading fully ... People,s Republic of China ("PRC"), announced today ... a proprietary breast drug from,Harbin Medical University ...
... Contribute to Blood Vessels, Healthy ... Ability to Relax, ... component of soy may enhance the function of arteries,in stroke patients, and ... and Prevention, heart disease is the,nation,s number one killer while stroke is ...
... Oct. 28 The Los Angeles Shambhala Center,presents a public ... the weekend, Oct 30 and November 1st and 2nd., ... Japan will,appear for the first time in Los Angeles at ... at Figueroa and Colorado Blvd.,in Eagle Rock., On Thursday, ...
... WellSpring Pharmaceutical,Corporation, a growing North American-based pharmaceutical manufacturer,today ... Operating Officer.,Formerly, Ms. Shusko held the position of ... 2000. In her new role as COO, Ms. ... of oversight,to operations with an initial focus on ...
... /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) ... initial closing of the financing announced on October,14, ... gross proceeds of $4.66,million. The closing involved a ... a price of $0.15 for each unit. Each ...
... for internet-based public reporting to help consumers ... WASHINGTON Oct. 28 To support consumer,engagement ... Quality Forum,(NQF) endorsed guidelines for consumer-focused, internet-based ... to present,information about hospital quality in an ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 2Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 3Health News:Study Shows How Soy Compound Lowers Blood Pressure and Stroke Risk 2Health News:Renowned Kyudo (Zen archery) Master Kanjuro Shibata Sensei to Present in L.A. 2Health News:WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 4Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 2Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 3Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 4Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 5
The Tri-Flex II system is a second generation healthcare patient support system that has the benefits of the original Tri-Flex system and multiple, updated support functions for increased comfort and...
... designed to make your bariatric patients feel comfortable ... them. , ,When caring for this population, ... in bed, turning, sitting, standing can be ... Care ES bed offers features to make these ...
... dignity. A single solution., ,Hill-Rom engineers ... added safety where its needed. Its long ... protect the caregiver and patient from injury, ... just like other TotalCare® beds, but its ...
... We offer a wide selection of solutions ... therapy use. The sterile water for inhalation ... in plastic pour bottles in 500 and ... prefilled nebulizer kits or can be used ...
Medicine Products: